A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma

This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP in the treatment of treatment-naïve patients with double expression DLBCL.

Trial Details

NCT ID

NCT05933967

Phase

PHASE2

Sponsor

Shandong Cancer Hospital and Institute

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Orelabrutinib+R-CHOP

Locations (sample)

Nanchang, Jiangxi, China|28.68396,115.85306
Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

Newly diagnosed Double Expression Diffuse Large B-cell Lymphoma
Age 18-70 years
ECOG performance status 0-2
Ann Arbor stage II-IV

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →